Key Highlights
- Sun Pharmaceutical Industries presented a binding all-cash acquisition proposal valued at $12 billion for Organon (OGN)
- Shares of OGN skyrocketed 41% to reach $8.25 on Friday, following an 18% climb to $6.91 the previous trading day
- The Indian pharmaceutical giant has conducted more than three months of comprehensive due diligence and is securing financing through JPMorgan and MUFG
- The transaction would represent the most significant international merger and acquisition by any Indian pharmaceutical firm if finalized
- Shares of Sun Pharmaceutical declined 3% on Mumbai exchanges amid the acquisition news
Organon has experienced a remarkable two-day trading surge. The women’s healthcare specialist headquartered in New Jersey saw its shares leap 41% Friday morning to $8.25, building on the previous day’s 18% increase, following news that Sun Pharmaceutical Industries had presented a formal $12 billion acquisition proposal.
According to India’s Economic Times, the Mumbai-headquartered pharmaceutical manufacturer has progressed past the due diligence phase and submitted a binding offer structured entirely in cash. Sun Pharma’s evaluation of this potential acquisition has spanned more than a quarter.
With Organon’s market capitalization currently hovering around $1.8 billion, the proposed $12 billion bid represents a significant premium above the company’s present market value.
The acquisition financing is being orchestrated with assistance from prominent financial institutions. Global banking powerhouses JPMorgan and Japan’s MUFG are among the key players facilitating Sun Pharma’s funding structure.
Understanding Organon’s Position
Organon emerged as an independent entity following its separation from Merck in 2021. The company specializes in women’s reproductive health, birth control, and fertility treatments, while maintaining additional product lines in dermatology, neurological conditions, and cardiovascular therapies.
The organization has navigated challenging circumstances recently. In October 2025, Chief Executive Kevin Ali resigned following an internal board inquiry that uncovered what the company characterized as inappropriate sales tactics employed to artificially boost quarterly performance metrics.
This isn’t Sun Pharma’s initial expression of interest in acquiring Organon. In January, the Economic Times disclosed that Sun Pharma had presented a preliminary, non-binding cash proposal and was gearing up to commence due diligence procedures. Friday’s developments represent significant advancement from those initial discussions.
Implications for Sun Pharmaceutical
Should the transaction reach completion, it would establish a new benchmark as the most substantial foreign acquisition in the history of Indian pharmaceutical companies — a milestone achievement for the industry.
Investors in Sun Pharmaceutical responded unfavorably to the announcement, with shares declining 3% on Mumbai exchanges Friday. Such market responses are typical when acquiring firms announce substantial debt-backed acquisitions.
Both Organon and Sun Pharmaceutical declined to provide statements to media inquiries at the time of publication.
Prior to this week’s dramatic rally, OGN shares had been trading at significantly reduced valuations. The consecutive gains of 18% followed by 41% mark a substantial reversal in market perception of the stock.
As of Friday morning, Sun Pharma is reportedly in the concluding phases of the bid process, with financing arrangements being finalized concurrent with the binding offer submission.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
